Nitric oxide releasing ultra-slippery antibacterial surfaces for urological catheter applications
Ended Project Grant Awarded Last action
- Award ID
- R43DK136411
- Recipient
-
Nytricx, Inc. UEI GF9DV4ACBHH8
- Awarding agency
-
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $337,395
Award facts
- Assistance listing
- 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research
- Completion date
- Place of performance
- Athens, GA 30602, USA
Award details come from USAspending.gov.
Description
- Abstract
- Urinary catheters are one of the most widely used medical devices in a hospital setting and are expected to only increase in growth due to the aging population. Out of all the various biomedical devices that are frequently used in a clinical setting, urinary catheters are associated with the largest portion of medical complications related to infection. Catheter associated urinary tract infections (CAUTIS) account for nearly 40% of all healthcare associated infections (HAIS) and can lead to extended hospital stays for patients which in turn leads to higher healthcare costs. To overcome this risk of infection, a catheter surface that is able to prevent bacterial adhesion and biofilm formation while simultaneously eliminating planktonic bacteria present in the vicinity is highly desirable. However, no long-term catheter solution has been able to accomplish this goal. Nytricx, INC. Has developed proprietary methods and know-how developing anti-infective nitric oxide (no) releasing interfaces capable of effectively eliminating a wide variety of bacterial strains while being able to elicit no cytotoxic response from mammalian cell lines. Nytricx, INC. Has also demonstrated that the liquid-infusion of silicone oil to create a super slippery surface is able to prevent the adhesion of proteins and bacteria and thus eliminate biofilms. A synergistic antimicrobial response is achieved by combining liquid-infused strategy and no releasing polymers (LINOREL). The overall objective of this phase I sbir application is to create a long-term highly antimicrobial urinary catheter through a combination of impregnating foley catheters with a no donor, S-nitroso-N- acetylpenicillamine (SNAP), with a liquid-infused silicone oil interface and to evaluate commercialization feasibility in terms of mechanical and biological properties.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $337,395 |
Quick answers
Who received award R43DK136411?
R43DK136411 was awarded to Nytricx, Inc. by National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) on July 15, 2023.
How much is award R43DK136411 worth?
$337,395 has been obligated on R43DK136411.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award